Skip to content
HowShorted

TG THERAPEUTICS, INC. short interest in 2024

In 2024, TG THERAPEUTICS, INC.'s disclosed short interest ran from 20.28% of shares outstanding on 12 Jan 2024 to 16.70% on 31 Dec 2024, a change of -3.58 percentage points. The year's high was 25.00% on 30 Apr 2024 and its low 16.70% on 31 Dec 2024, averaging 20.92% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.80 days on 14 Jun 2024. Full history: TG THERAPEUTICS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for TG THERAPEUTICS, INC. in 2024

2024 in figures

Start of year
20.28% (12 Jan 2024)
End of year
16.70% (31 Dec 2024)
Change
-3.58 pp
High
25.00% (30 Apr 2024)
Low
16.70% (31 Dec 2024)
Average
20.92%
Highest days to cover
15.80 (14 Jun 2024)
SEC filings marked
8

Every report in 2024

TG THERAPEUTICS, INC. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 202420.28%3.64
31 Jan 202419.23%7.19
15 Feb 202423.63%9.55
29 Feb 202423.01%6.37results (8-K), 10-K filed
15 Mar 202422.58%9.26
28 Mar 202422.69%15.79
15 Apr 202423.59%14.46
30 Apr 202425.00%12.15
15 May 202422.19%6.32results (8-K), 10-Q filed
31 May 202421.58%15.03
14 Jun 202421.71%15.80
28 Jun 202421.16%11.22
15 Jul 202420.82%12.32
31 Jul 202420.17%12.75
15 Aug 202421.13%8.15results (8-K), 10-Q filed
30 Aug 202419.06%8.91
13 Sep 202419.27%8.79
30 Sep 202422.22%5.89
15 Oct 202420.98%13.16
31 Oct 202420.67%13.96
15 Nov 202418.20%5.11results (8-K), 10-Q filed
29 Nov 202418.68%10.31
13 Dec 202417.43%14.01
31 Dec 202416.70%13.25

See also: TG THERAPEUTICS, INC.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.